bkyi20230726_8k.htm
false 0001019034 0001019034 2023-07-24 2023-07-24
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 24, 2023
 
BIO-key International, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
(State or other jurisdiction of incorporation)
1-13463
(Commission File Number)
41-1741861
(I.R.S. Employer Identification No.)
 
3349 Highway 138, Building A, Suite E
Wall, NJ 07719
(Address of principal executive offices)
 
(732) 359-1100
(Registrant’s telephone number, including area code)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
BKYI
Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
 
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
 
Item 5.07 Submission of Matters to a Vote of Security Holders.
 
BIO-key International, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on Monday, July 24, 2023. All holders of record of the Company’s common stock outstanding as of the close of business on June 1, 2023 were entitled to vote at the Annual Meeting. At the Annual Meeting, stockholders approved the proposals set forth below. Each of the proposals is more fully described in the Company’s definitive proxy statement, which was filed with the Securities and Exchange Commission on June 9, 2023.
 
1.         Proposal to elect the following nominees to serve as members of the Company’s board of directors for a one-year term: Michael W. DePasquale, Wong Kwok Fong (Kelvin), Thomas E. Bush, III, Robert J. Michel, Emmanuel Alia, and Cameron E. Williams. Each of the nominees were elected and the final voting results were as follows:
 
Name
 
Votes For
   
Withheld
   
Broker Non-Votes
 
                         
Michael DePasquale
    2,257,370       511,573       2,740,194  
Wong Kwok Fong (Kelvin)
    2,261,052       507,891       2,740,194  
Thomas E. Bush, III
    2,275,350       495,593       2,740,194  
Robert J. Michel
    1,783,395       985,548       2,740,194  
Emmanuel Alia
    2,056,284       712,659       2,740,194  
Cameron E. Williams
    1,776,537       992,406       2,740,194  
 
2.          Proposal to ratify the selection of Marcum LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The proposal was approved and the final voting results were as follows:
 
Votes For
   
Votes Against
   
Abstentions
   
Broker Non-Votes
 
4,139,367       1,294,602       75,168       0  
 
3. Proposal to approve, on a non-binding and advisory basis, the compensation paid to the Company’s named executive officers.  The proposal was approved and the final voting results were as follows:
 
Votes For
   
Votes Against
   
Abstentions
   
Broker Non-Votes
 
2,117,139       588,218       63,586       2,740,194  
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
BIO-KEY INTERNATIONAL, INC.
 
Date: July 26, 2023
     
 
By:
/s/ Cecilia C. Welch
 
   
Cecilia C. Welch
 
   
Chief Financial Officer